Progressive multifocal leukoencephalopathy in a patient with B-cell chronic lymphocytic leukemia after COVID-19 vaccination, complicated with COVID-19 and mucormycosis: a case report.
B-CLL
COVID-19
Mucormycosis
PML
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
04 May 2024
04 May 2024
Historique:
received:
12
02
2023
accepted:
23
04
2024
medline:
5
5
2024
pubmed:
5
5
2024
entrez:
4
5
2024
Statut:
epublish
Résumé
Progressive multifocal leukoencephalopathy (PML) is a rare and fatal opportunistic viral demyelinating infectious disease of the central nervous system (CNS). There are various clinical presenting symptoms for the disease. This paper presents a clinical case of PML in a patient with B-Chronic lymphocytic leukemia (B-CLL), previously treated with Chlorambucil, later complicated later with COVID-19 and mucormycosis. PML can develop in the setting of cellular immune dysfunction. Late diagnosis of this disease based on nonspecific symptoms is common, therefore when we face a neurological complication in a CLL or immunocompromised patient, we should consider PML infection. A remarkable feature of this case is the possible triggering effect of COVID-19 vaccination for emergence of PML as the disease can be asymptomatic or sub-clinical before diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Progressive multifocal leukoencephalopathy (PML) is a rare and fatal opportunistic viral demyelinating infectious disease of the central nervous system (CNS). There are various clinical presenting symptoms for the disease.
CASE PRESENTATION
METHODS
This paper presents a clinical case of PML in a patient with B-Chronic lymphocytic leukemia (B-CLL), previously treated with Chlorambucil, later complicated later with COVID-19 and mucormycosis.
CONCLUSION
CONCLUSIONS
PML can develop in the setting of cellular immune dysfunction. Late diagnosis of this disease based on nonspecific symptoms is common, therefore when we face a neurological complication in a CLL or immunocompromised patient, we should consider PML infection. A remarkable feature of this case is the possible triggering effect of COVID-19 vaccination for emergence of PML as the disease can be asymptomatic or sub-clinical before diagnosis.
Identifiants
pubmed: 38704555
doi: 10.1186/s12883-024-03650-y
pii: 10.1186/s12883-024-03650-y
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
151Informations de copyright
© 2024. The Author(s).
Références
KARL-ERIK ASTROM EL, MANCALL, AND J. EDWARD P. RICHARDSON, Multifocal Leuko-Encephalopathy: A Hitherto Unrecognized Complication Of Chronic Lymphatic Leukemia And Hodgkin’s Disease 1958.
Arseni C, Nereanţiu F. Progressive Multifocal Leukoencephalopathy Eur Neurol. 1971;5(5):270–80.
pubmed: 5133549
Bag AK, et al. JC virus infection of the brain. AJNR Am J Neuroradiol. 2010;31(9):1564–76.
doi: 10.3174/ajnr.A2035
pubmed: 20299430
pmcid: 7965014
Mansoor S, et al. Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): a case report from Ireland with review of literature, clinical pitfalls and future direction. Egypt J Neurol Psychiatr Neurosurg. 2021;57(1):7.
doi: 10.1186/s41983-020-00260-6
pubmed: 33437143
pmcid: 7789894
Kartau M, et al. Progressive Multifocal Leukoencephalopathy: current insights. Degener Neurol Neuromuscul Dis. 2019;9:109–21.
pubmed: 31819703
pmcid: 6896915
Anand P et al. Progressive multifocal leukoencephalopathy: a 25-year retrospective cohort study. Neurol Neuroimmunol Neuroinflamm, 2019. 6(6).
D’Souza A, et al. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk. 2010;10(1):E1–9.
doi: 10.3816/CLML.2010.n.009
pubmed: 20223720
Amend KL, et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology. 2010;75(15):1326–32.
doi: 10.1212/WNL.0b013e3181f73600
pubmed: 20938025
Danovska M, et al. Chlorambucil- Induced progressive multifocal leucoencephalopathy - a case report. J Neurol Sci. 2019;405:166.
doi: 10.1016/j.jns.2019.10.1095
Dhakal B, et al. Progressive multifocal leukoencephalopathy in the background of chlorambucil treated chronic lymphocytic leukemia: a case report from Nepal. Ann Med Surg (Lond). 2023;85(10):5167–70.
doi: 10.1097/MS9.0000000000001190
pubmed: 37811014
Burnette WB. Case 15: when a stroke is not a stroke. MedGenMed. 2007;9(1):21.
pubmed: 17435628
pmcid: 1924978
Zhang Y, Wright C, Flores A. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature. J Med Case Rep. 2018;12(1):187.
doi: 10.1186/s13256-018-1727-7
pubmed: 29960601
pmcid: 6026501
Miskin DP, Ngo LH, Koralnik IJ. Diagnostic delay in progressive multifocal leukoencephalopathy. Ann Clin Transl Neurol. 2016;3(5):386–91.
doi: 10.1002/acn3.301
pubmed: 27231708
pmcid: 4863751
Möhn N, et al. Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy. Fluids Barriers CNS. 2020;17(1):65.
doi: 10.1186/s12987-020-00227-y
pubmed: 33109245
pmcid: 7590675
Infante MT et al. A case of atypical progressive multifocal encephalopathy mimicking acute ischemic stroke: case report and review of literature. Neuroimmunol Neuroinflammation, 2017. 4(10).
Neil EC, DeAngelis LM. Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review. Blood Adv. 2017;1(23):2041–5.
doi: 10.1182/bloodadvances.2017008201
pubmed: 29296850
pmcid: 5728282
Pavlovic D, et al. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8(6):255–73.
doi: 10.1177/1756285615602832
pubmed: 26600871
pmcid: 4643867
Manouchehri N, Steinman L, Stuve O. Biological significance of Anti-SARS-CoV-2 antibodies: lessons learned from Progressive Multifocal Leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm, 2021. 8(2).
Özbek L, et al. COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases. Clin Microbiol Infect. 2023;29(6):722–31.
doi: 10.1016/j.cmi.2023.03.008
pubmed: 36921716
pmcid: 10008766
Kiernan K, MacIver NJ. Viral infection interferes with glucose tolerance. Immunity. 2018;49(1):6–8.
doi: 10.1016/j.immuni.2018.06.013
pubmed: 30021147
Gerganova A, Assyov Y, Kamenov Z. Stress hyperglycemia, diabetes Mellitus and COVID-19 infection: risk factors, clinical outcomes and post-discharge implications. Front Clin Diabetes Healthc. 2022;3:826006.
doi: 10.3389/fcdhc.2022.826006
pubmed: 36992767
pmcid: 10012081